

Agnieszka Jankowska

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4117352/publications.pdf>

Version: 2024-02-01

21
papers

294
citations

933447

10
h-index

888059

17
g-index

21
all docs

21
docs citations

21
times ranked

372
citing authors

#	ARTICLE	IF	CITATIONS
1	PDE7-Selective and Dual Inhibitors: Advances in Chemical and Biological Research. Current Medicinal Chemistry, 2017, 24, 673-700.	2.4	41
2	Novel butanehydrazide derivatives of purine-2,6-dione as dual PDE4/7 inhibitors with potential anti-inflammatory activity: Design, synthesis and biological evaluation. European Journal of Medicinal Chemistry, 2018, 146, 381-394.	5.5	37
3	A Novel, Pan-PDE Inhibitor Exerts Anti-Fibrotic Effects in Human Lung Fibroblasts via Inhibition of TGF- β^2 Signaling and Activation of cAMP/PKA Signaling. International Journal of Molecular Sciences, 2020, 21, 4008.	4.1	28
4	Novel amide derivatives of 1,3-dimethyl-2,6-dioxopurin-7-yl-alkylcarboxylic acids as multifunctional TRPA1 antagonists and PDE4/7 inhibitors: A new approach for the treatment of pain. European Journal of Medicinal Chemistry, 2018, 158, 517-533.	5.5	27
5	Advances in Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 1: Overview of the Chemical and Biological Research. Current Drug Targets, 2018, 20, 122-143.	2.1	23
6	Multi-Target-Directed Ligands Affecting Serotonergic Neurotransmission for Alzheimer's Disease Therapy: Advances in Chemical and Biological Research. Current Medicinal Chemistry, 2018, 25, 2045-2067.	2.4	20
7	Novel anilide and benzamide derivatives of arylpiperazinylalkanoic acids as 5-HT _{1A} /5-HT ₇ receptor antagonists and phosphodiesterase 4/7 inhibitors with procognitive and antidepressant activity. European Journal of Medicinal Chemistry, 2020, 201, 112437.	5.5	19
8	Computer-aided insights into receptor-ligand interaction for novel 5-arylhydantoin derivatives as serotonin 5-HT ₇ receptor agents with antidepressant activity. European Journal of Medicinal Chemistry, 2018, 147, 102-114.	5.5	16
9	Novel phosphodiesterases inhibitors from the group of purine-2,6-dione derivatives as potent modulators of airway smooth muscle cell remodelling. European Journal of Pharmacology, 2019, 865, 172779.	3.5	13
10	Synthesis and in vitro evaluation of anti-inflammatory, antioxidant, and anti-fibrotic effects of new 8-aminopurine-2,6-dione-based phosphodiesterase inhibitors as promising anti-asthmatic agents. Bioorganic Chemistry, 2021, 117, 105409.	4.1	11
11	Multifunctional Ligands Targeting Phosphodiesterase as the Future Strategy for the Symptomatic and Disease-Modifying Treatment of Alzheimer's Disease. Current Medicinal Chemistry, 2020, 27, 5351-5373.	2.4	10
12	Advances in the Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 2: Focus on Schizophrenia. Current Drug Targets, 2019, 20, 1652-1669.	2.1	10
13	Multifunctional Ligands with Glycogen Synthase Kinase 3 Inhibitory Activity as a New Direction in Drug Research for Alzheimer's Disease. Current Medicinal Chemistry, 2021, 28, 1731-1745.	2.4	9
14	Estimation of the lipophilicity of purine-2,6-dione-based TRPA1 antagonists and PDE4/7 inhibitors with analgesic activity. Bioorganic and Medicinal Chemistry Letters, 2021, 49, 128318.	2.2	7
15	Discovery and Development of Non-Dopaminergic Agents for the Treatment of Schizophrenia: Overview of the Preclinical and Early Clinical Studies. Current Medicinal Chemistry, 2019, 26, 4885-4913.	2.4	7
16	Diabetic Theory in Anti-Alzheimer's Drug Research and Development - Part 1: Therapeutic Potential of Antidiabetic Agents. Current Medicinal Chemistry, 2020, 27, 6658-6681.	2.4	6
17	Pan-Phosphodiesterase Inhibitors Attenuate TGF- β^2 -Induced Pro-Fibrotic Phenotype in Alveolar Epithelial Type II Cells by Downregulating Smad-2 Phosphorylation. Pharmaceuticals, 2022, 15, 423.	3.8	4
18	Diabetic Theory in Anti-Alzheimer's Drug Research and Development. Part 2: Therapeutic Potential of cAMP-Specific Phosphodiesterase Inhibitors. Current Medicinal Chemistry, 2021, 28, 3535-3553.	2.4	2

#	ARTICLE	IF	CITATIONS
19	A new class of 5-HT1A receptor antagonists with procognitive and antidepressant properties. Future Medicinal Chemistry, 2021, 13, 1497-1514.	2.3	2
20	Design and Synthesis of Novel Aminoalkanamides Targeting Neurodegeneration and Symptoms of Alzheimer's Disease. Current Medicinal Chemistry, 2021, 28, 6082-6094.	2.4	2
21	Design and synthesis of new anilide and benzylamide derivatives as potential multifunctional ligands with procognitive and antidepressant activity. Postępy Polskiej Medycyny i Farmacji, 2022, 9, 1-8.	0.0	0